Afatinib in NSCLC With HER2 Mutation

Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

NCT02695290 ·Status: TERMINATED ·Phase: PHASE4

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

NCT01746251 ·Status: UNKNOWN ·Phase: PHASE2

Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC

NCT02625168 ·Status: COMPLETED ·Phase: PHASE2

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

NCT01931306 ·Status: APPROVED_FOR_MARKETING

A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma

NCT02491099 ·Status: RECRUITING ·Phase: PHASE2

An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

NCT03810872 ·Status: UNKNOWN ·Phase: PHASE2

To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC

NCT05818982 ·Status: RECRUITING ·Phase: PHASE2

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

NCT04201756 ·Status: COMPLETED ·Phase: PHASE2

A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)

NCT01480141 ·Status: WITHDRAWN ·Phase: PHASE2

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

NCT04439136 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

NCT06709859 ·Status: RECRUITING ·Phase: PHASE2

Afatinib Genomic Landscape

NCT02491775 ·Status: TERMINATED

To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation

NCT04132102 ·Status: UNKNOWN ·Phase: PHASE4

The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC)

NCT03811054 ·Status: UNKNOWN ·Phase: PHASE2

Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex

NCT02876081 ·Status: WITHDRAWN ·Phase: PHASE2

Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA

NCT02629523 ·Status: COMPLETED ·Phase: PHASE2

Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

NCT02044380 ·Status: COMPLETED ·Phase: PHASE3

Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.

NCT02470065 ·Status: SUSPENDED ·Phase: PHASE2

A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene

NCT02506517 ·Status: COMPLETED ·Phase: PHASE2

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

NCT05070403 ·Status: RECRUITING ·Phase: PHASE2

Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma

NCT03486509 ·Status: UNKNOWN ·Phase: PHASE2

Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

NCT02064491 ·Status: COMPLETED ·Phase: PHASE2

Afatinib With CT and RT for EGFR-Mutant NSCLC

NCT01553942 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer

NCT01542437 ·Status: COMPLETED ·Phase: PHASE2

Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer

NCT03727724 ·Status: COMPLETED ·Phase: PHASE2